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ABSTRACT	  
Liver	  X	  Receptor	  β	  (LXRβ)	  is	  a	  nuclear	  receptor,	  belonging	  to	  the	  superfamily	  of	  ligand-­‐activated	  
transcription	   factors.	  With	   its	  α	   isoform	  (LXRα),	   LXRβ	   shares	  more	   than	  78%	  homology	   in	   its	  
amino	   acid	   sequence,	   a	   common	   profile	   of	   oxysterol	   ligands	   and	   the	   heterodimerization	  
partner,	   Retinoid	   X	   Receptor.	   LXRs	   have	   a	   crucial	   role	   in	   lipid	   metabolism,	   in	   particular	   in	  
preventing	  cholesterol	  accumulation,	  in	  glucose	  homeostasis	  and	  in	  macrophage	  inflammatory	  
response.	  The	  first	  evidence	  that,	   in	  spite	  of	  all	  the	  common	  properties,	  LXRα	  and	  LXRβ	  have	  
distinct	   functions,	   came	   in	   2001	  with	   the	   creation	   of	   knock-­‐out	  mice	   for	   each	   LXR	   isoform.	  
LXRα-­‐/-­‐	  mice	  fed	  with	  2%	  cholesterol	  diet	  show	  a	  severe	  cholesterol	  accumulation	  in	  the	  liver	  
due	   to	   an	   inability	   to	   increase	   bile	   acid	   synthesis	   in	   response	   to	   high	   cholesterol	   intake.	  
Surprisingly,	  LXRβ-­‐/-­‐	  mice	  had	   the	  same	  compensatory	  capacity	  of	  WT	  mice	   to	  avoid	  hepatic	  
cholesterol	  accumulation	  suggesting	  that	  LXRβ	  may	  have	  a	  completely	  distinct	  role	  from	  LXRα.	  
Indeed	  in	  2005,	  it	  was	  shown	  that	  specifically	  in	  LXRβ-­‐/-­‐	  male	  mice	  cholesterol	  accumulates	  in	  
big	  motor	  neurons	  of	   the	  spinal	   cord	   leading	   to	   their	  death	  and	   inducing	  a	   significant	  motor	  
function	   impairment	   like	   amyotrophic	   lateral	   sclerosis	   (ALS).	   Starting	   from	   this	   neurological	  
phenotype	  of	  LXRβ-­‐/-­‐	  mice	  and	  comparing	  the	  characteristics	  of	  knock-­‐out	  mice	  for	  each	  LXR	  
isoform,	  this	  thesis	  aims	  to	  define	  new	  and	  specific	  functions	  of	  the	  oxysterol	  receptor	  LXRβ.	  
Paper	  I	  of	  this	  thesis	  aims	  to	  investigate	  the	  neurological	  phenotype	  of	  LXRβ-­‐/-­‐	  mice	  focusing	  in	  
particular	   on	   the	   role	   of	   β-­‐sitosterol	   in	   the	   pathogenesis	   ALS-­‐Parkinson-­‐Dementia	   complex.	  
Administration	  of	  β-­‐sitosterol	  to	  LXRβ-­‐/-­‐	  mice	  creates	  a	  severe	  motor-­‐impairment	  and	  loss	  of	  
dopaminergic	   neurons	   in	   the	   substantia	   nigra,	   activates	   microglia	   and	   decreases	   brain	  
cholesterol	   indicating	   that	   LXRβ	   may	   have	   a	   protective	   role	   against	   the	   toxic	   action	   of	   β-­‐
sitosterol	  on	  the	  central	  nervous	  system.	  
Paper	   II	   investigates	   the	   resistance	   to	   gain	   weight,	   characteristic	   of	   LXRβ-­‐/-­‐	   mice	   and	  
demonstrates	  that	  they	  are	  affected	  by	  a	  severe	  pancreatic	  insufficiency	  with	  low	  serum	  levels	  
of	   amylase,	   lipase,	   low	   fecal	   protease	   and	   abundant	   inflammatory	   infiltrates	   all	   around	  
medium	   size	   pancreatic	   ducts.	   The	   water	   channel	   aquaporin-­‐1	   (AQP-­‐1),	   responsible	   of	  
transporting	  water	   into	  the	  pancreatic	  ductal	   lumen	  was	  markedly	  decreased	  in	  LXRβ-­‐/-­‐	  mice	  
leading	  to	  the	  presence	  of	  plugs	  inside	  the	  ducts	  and	  in	  turn	  to	  a	  pancreatic	  insufficiency.	  
In	   the	   digestive	   system	  AQP-­‐1	   is	   strongly	   expressed	   in	   the	   cholangiocytes	   of	   the	   gallbladder	  
being,	   together	  with	  AQP-­‐8,	   the	  mediator	  of	   the	  absorbing-­‐secretory	   functions	  of	   this	  organ.	  
Paper	   III	   shows	   that	   the	   male	   gallbladder	   cholangiocytes	   of	   LXRβ-­‐/-­‐	   mice	   express	   very	   low	  
mRNA	  and	  protein	   levels	  of	  both	  AQP-­‐1	  and	  AQP-­‐8	  and	  morphologically	   they	  appear	   shrunk	  
with	  loss	  of	  cell	  polarization.	  Treatment	  of	  WT	  mice	  with	  LXR-­‐agonist	  increases	  the	  expression	  
of	   the	   two	  water	   channels	   in	   the	  gallbladder	   together	  with	   the	   cholesterol	   transporters	  ATP	  
Binding	  Cassette	  G5/G8	  and	  it	  is	  associated	  with	  cholesterol	  crystals	  in	  the	  bile.	  
The	   morphology	   of	   female	   LXRβ-­‐/-­‐	   gallbladders	   was	   studied	   in	   paper	   IV:	   at	   the	   age	   of	   12	  
months	  a	  wide	  range	  of	  preneoplastic	  lesions	  are	  detectable,	  from	  dysplasia	  to	  metaplasia	  and	  
adenomas,	  degenerating	   into	   carcinoma	   in	   situ,	  when	   the	  mice	  become	  19	  months	  old.	   The	  
pathogenesis	   involves	   a	   complex	   interplay	   between	   LXRβ,	   Transforming	   Growth	   Factor	   β	  
(TGFβ)	   and	   estrogens.	   Indeed,	   ovariectomy	   of	   LXRβ-­‐/-­‐	   mice	   prevents	   the	   development	   of	  
preneoplastic	  lesions	  and	  normalizes	  the	  TGFβ	  signaling	  that	  is	  upregulated	  in	  LXRβ-­‐/	  mice.	  
In	  conclusion,	  this	  thesis	  describes	  new	  emerging	  and	  specific	  roles	  for	  LXRβ	  in	  controlling	  not	  
only	  cholesterol	  homeostasis	  in	  the	  central	  nervous	  system	  but	  also	  water	  channels	  in	  pancreas	  
and	  gallbladder	  as	  well	  neoplastic	  transformation	  of	  cholangiocytes. 
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  1 
1 INTRODUCTION	  
1.1 NUCLEAR	  RECEPTORS	  
1.1.1 Milestones	  in	  nuclear	  receptor	  research	  
Nuclear	  Receptors	  (NR)	  are	  a	   large	  super	  family	  of	  transcription	  factors	  whose	  discovery	  has	  
opened	  new	  frontiers	  in	  understanding	  not	  only	  the	  endocrine	  action	  of	  steroid	  hormones	  but	  
also	   and	   especially,	   the	   “hormonal	   behavior”	   of	   canonical	   non-­‐hormonal	  molecules	   such	   as	  
oxysterols,	  bile	  acids	  and	  vitamins.	  
Some	  members	  of	  this	  superfamily	  are	  ligand-­‐activated,	  and	  act	  as	  transcription	  factors	  upon	  
binding	   to	   small	   biologically	   active	  molecules.	   Activated	   receptors	   can	   bind	   to	   specific	   DNA	  
sequences	   (response	  elements)	   in	   the	  promoter	  of	   target	   genes,	   or	   can	   interact	  with	  other	  
transcription	  factors	  to	  activate	  or	  inhibit	  transcription.	  
The	  epoch	  of	  nuclear	  receptor	  research	  started	  at	  the	  end	  of	  1950s	  with	  the	  observation	  that	  
the	   injection	   of	   radioactive	   estradiol	   into	   rats	   had	   a	   tissue	   specific	   uptake	   and	   retention	  
pattern,	   indicating	   the	   existence	   of	   a	   protein	   capable	   of	   binding	   to	   estradiol	   [1-­‐3].	   These	  
studies	   by	   Elwood	   Jensen	   culminated	   in	   the	   identification	   in	   the	   uterus	   of	   estrophilin,	   an	  
estradiol-­‐binding	   protein,	   afterwards	   named	   estrogen	   receptor	   (ER)	   and	   subsequently	  
identified	  as	  a	  nuclear	  receptor	  [4].	  
A	  plethora	  of	  subsequent	  	  studies,	  in	  particular	  the	  action	  of	  progesterone	  on	  chick	  oviducts,	  
led	  to	  our	  present	  	  understanding	  of	  the	  physiological	  steps	  in	  nuclear	  receptor	  signalling.	  It	  is	  
generally	  accepted	  that	   	  steroid	  hormones	  bind	  to	  their	  specific	  receptors	  which	  are	  located	  
either	  in	  the	  nucleus	  or	  cytoplasm.	  Cytoplasmic	  receptors	  migrate	  to	  the	  nucleus	  upon	  binding	  
to	  their	   ligands.	   In	  the	  nucleus,	  activated	  receptors	  bind	  to	  specific	  sites	  on	  DNA	  and	  induce	  
the	   transcription	   of	   specific	   mRNA	   and	   in	   turn	   the	   synthesis	   of	   protein	   involved	   in	   tissue	  
differentiation,	  proliferation	  or	  metabolism	  [5-­‐8].	  
It	  was	  at	  the	  end	  of	  1970s	  that	  the	  first	  nuclear	  receptor,	  the	  glucocorticoid	  receptor	  (GR)	  was	  
purified	   [9]	   and	   its	   three	   domains	   were	   identified:	   a	   ligand-­‐binding	   domain	   (LBD),	   a	   DNA-­‐
  2 
binding	  domain	   (DBD)	   and	   a	   third	   strongly	   immunogenic	   domain	   [10].	   Thanks	   to	   the	  highly	  
conserved	  structure	  of	  nuclear	  receptors	  and	  their	  homology	  in	  the	  DBD,	  in	  “the	  cloning	  era”	  
of	  the	  1980s,	  it	  was	  possible	  to	  clone	  many	  previously	  unknown	  nuclear	  receptors.	  Thus	  in	  a	  
process	  called	  “reverse	  endocrinology”,	  it	  was	  discovered	  that	  there	  were	  many	  more	  nuclear	  
receptors	  than	  there	  were	  steroid	  hormones.	  Those	  receptors	  whose	  ligands	  were	  not	  known	  
were	  called	  	  “orphans”	  [11].	  
Over	  the	  past	  15	  years,	  48	  members	  of	  the	  NR	  superfamily	  have	  been	  identified	  in	  the	  human	  
genome	  and	  many	  NR	  ligands	  are	  now	  targets	  for	  pharmacological	  interventions	  [12].	  
	  
1.1.2 Structure	  
Nuclear	   receptors	   share	   a	   canonical	   structure,	   composed	   of	   functionally	   distinct	   domains	  
(Figure	  1):	  the	  N-­‐terminal	  activation	  function	  1	  (AF1)	  domain,	  highly	  variable	  in	  sequence	  and	  
length	   [13,	   14];	   the	   highly	   conserved	   DNA-­‐binding	   domain	   (DBD)	   that	   contains	   two	   zinc-­‐
binding	  motifs,	   involved	  not	  only	   in	  DNA	  binding	  but	  also	   in	  receptor	  dimerization	  [15];	  and	  
the	   C-­‐terminal	   ligand	   binding	   domain	   (LBD)	   with	   a	   key	   role	   in	   ligand	   binding,	   nuclear	  
localization,	  receptor	  dimerization	  and	  interaction	  with	  coactivators	  and	  corepressors	  [16,	  17].	  
Between	   the	  DBD	  and	   LBD	   is	   the	  hinge	  domain	   that	   provides	   flexibility	   between	   these	   two	  
domains.	  The	  AF2	  domain	  lies	  within	  the	  LBD.	  AF2	  adopts	  different	  conformations	  depending	  
on	  the	  structure	  of	  the	  ligand	  which	  is	  bound	  in	  the	  ligand-­‐binding	  pocket.	  In	  general,	  agonists	  
induce	   conformations	   that	   are	   recognized	   by	   coactivators,	   while	   antagonists	   induce	  
conformations	  recognized	  by	  corepressors.	  	  
	  
1.2 LIVER	  X	  RECEPTORS	  
Liver	  X	  Receptors	  (LXRs)	  are	  nuclear	  receptors	  first	   identified	  as	  “orphans”	  but	  subsequently	  
adopted	  by	  oxygenated	   cholesterol	   derivates	   [18].	   There	   are	   two	   isoforms	  with	  78%	  amino	  
acid	  homology	   in	   their	  DNA-­‐binding	  domain	  and	   ligand-­‐binding	  domain.	   LXRα	   (NR1H3),	   first	  
discovered	   by	  Magnus	   Pfahl	   and	   called	   RLD1	   [19,	   20],	   and	   LXRβ	   (NR1H2)	   [21]	   also	   named	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ubiquitous	   receptor	   [22],	   NER	   [23]	   or	   orphan	   receptor-­‐1	   [24]	   because	   of	   its	   concomitant	  
independent	   discovery	   by	   four	   different	   laboratories.	   In	   humans,	   LXRα	   is	   located	   on	  





	   	  
	  
	   	  
	  
Figure	  1.	  Conserved	  structure	  of	  Nuclear	  Receptors	  containing	  the	  following	  domains:	  the	  N-­‐terminal	  activation	  
function	   1	   (AF1)	   domain,	   highly	   variable	   between	  nuclear	   receptors;	   the	  DNA-­‐binding	   domain	   very	   conserved	  
between	  members;	   the	  hinge	   region,	  a	   flexible	  domain	  between	   the	  DBD	  and	  LBD;	   the	   ligand-­‐binding	  domain	  
involved	  in	  the	  interaction	  with	  ligands;	  the	  AF2	  domain	  that	  is	  a	  part	  of	  LBD	  whose	  different	  conformations	  are	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1.2.1 Tissue	  distribution	  of	  LXRs	  
In	  adult	  mice,	  mRNA	  of	  the	  two	  LXRs	  isoforms	  have	  been	  detected	  with	  a	  different	  distribution	  
profile.	   LXRα	   is	   highly	   expressed	   in	   the	   liver,	   adipose	   tissue,	   intestine,	   kidney,	   and	  
macrophages	  while	  LXRβ	  mRNA	   is	  ubiquitously	  expressed	  with	  high	   levels	   in	   the	  developing	  
brain	  [25,	  26].	  
During	  mouse	  development,	   starting	   from	  embryonic	  day	  11.5,	   both	   LXRα	   and	   LXRβ	  mRNA	  
are	  detected	  in	  the	  liver.	  LXRα	  maintains	  high	  expression	  throughout	  life	  while,	  hepatic	  LXRβ	  
decreases	  during	  later	  embryonic	  development	  [27].	  Between	  mouse	  embryo	  ages	  days	  11.5	  
and	  16.5,	  LXRα	  mRNA	  appears	  to	  be	  detectable	   in	  brown	  adipose	  tissue,	   thyroid	  gland,	  and	  
intestine	   while	   LXRβ	   mRNA	   is	   strongly	   expressed	   in	   brain,	   retina,	   ganglia	   (tibulocochlear,	  
trigeminal,	  dorsal	  root),	  kidney,	  adrenal,	  thymus	  and	  thyroid	  gland	  [27].	  
In	   the	   brain,	   LXRβ	   protein	   expression	   is	   detectable	   as	   early	   as	   embryo	   age	   day	   14.5	   in	   the	  
neurons	  of	  the	  cortical	  plate	  [28].	  
	  
1.2.2 Ligands	  
A	  wide	  range	  of	  molecules,	  both	  natural	  and	  synthetic	  has	  been	  shown	  to	  be	  potential	  ligands	  
of	  LXR	  in	  in	  vitro	  assays	  [29].	  
The	   first	   identified	   natural	   ligands	   that	   can	   activate	   LXRs	   at	   physiological	   concentration	   are	  
oxysterols,	   in	   particular	   24(S)-­‐hydroxycholesterol,	   22(R)-­‐hydroxycholesterol,	   24(S),25-­‐
epoxycholesterol,	  27-­‐hydroxycholesterol	  [18]	  and	  its	  metabolite,	  cholestenoic	  acid	  [30].	   	  The	  
synthesis	  of	  24(S)-­‐hydroxycholesterol	  from	  cholesterol	  is	  catalysed	  by	  the	  enzyme	  cytochrome	  
P450	  46	  A1	  (CYP46A1).	  	  This	  is	  a	  key	  pathway	  in	  brain	  cholesterol	  homeostasis	  since	  it	  is	  the	  
main	  mechanism	   of	   cholesterol	   removal	   from	   the	   brain	   [31].	   22(R)-­‐hydroxycholesterol	   is	   a	  
naturally	   occurring	   oxysterol	   while	   24(S),25-­‐epoxycholesterol	   is	   made	   in	   a	   shunt	   during	  
cholesterol	   synthesis	   pathway	   from	   the	   cholesterol	   precursor	   squalene	   [32].	   27-­‐
Hydroxycholesterol	   is	   generated	   by	   a	   mitochondrial	   P450	   enzyme,	   CYP27,	   involved	   in	   the	  
alternative	  bile	  acid	  synthesis	  pathway	  [33].	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It	   is	   therefore	   intriguing	   that	   both	   enzymes	   metabolizing	   and	   catabolizing	   oxysterols,	  
respectively,	  may	  participate	  in	  the	  regulation	  of	  LXR	  activity.	  Emerging	  in	  vivo	  studies	  support	  
this	  notion.	  Knockout	  mice	  engineered	   to	  delete	  enzymes	   synthesizing	  24(S)-­‐HC,	  25-­‐HC	  and	  
27-­‐HC	  are	  unable	   to	   induce	   LXR	   target	   genes	   in	   response	   to	  dietary	   cholesterol	   but	   remain	  
responsive	   to	   a	   synthetic	   LXR	   agonist	   (T0901317)	   [34].	   Moreover,	   treatment	   of	   mice	   with	  
inhibitors	  of	  cholesterol	  synthesis	  such	  as	  the	  archetypal	  statin,	  compactin,	  leads	  to	  a	  decrease	  
in	   the	   synthesis	   of	   24(S),25-­‐epoxycholesterol,	   and	   to	   a	   decreased	   expression	   of	   LXR	   target	  
genes	   [35,	   36].	   Conversely,	   in	   mice,	   adenovirus-­‐mediated	   overexpression	   of	   cholesterol	  
sulfotransferase,	   (SULT2A1)	   an	   enzyme	   capable	   of	   catabolizing	   oxysterols,	   prevents	   dietary	  
induction	  of	  hepatic	  LXR	  target	  genes	  by	  dietary	  cholesterol	  but	  not	  by	  T0901317	  [34].	  
D-­‐glucose	   has	   been	   reported	   capable	   of	   binding	   to	   both	   LXRα	   and	   LXRβ	   and	   inducing	   LXR	  
transcriptional	  activity	  [37].	  This	  role	  of	  LXRs	  as	  glucose	  sensors	  is	  not	  well	  understood	  since	  
only	  the	  transcription	  factor	  carbohydrate-­‐responsive	  element	  binding	  protein	  (ChREBP),	  and	  
not	   LXRs,	   has	   been	   shown	   to	   induce	   glucose-­‐regulated	   genes	   in	   the	   liver	   in	   presence	   of	  
glucose	  [38].	  
Phytosterols,	  in	  particular	  β-­‐sitosterol	  have	  also	  been	  recognized	  as	  ligands	  for	  LXRs	  [39].	  
Moreover,	   two	   non-­‐steroidal	   synthetic	   compounds,	   GW3965	   and	   T0901317	   have	   been	  
identified	  as	  LXR	  agonists	  [40,	  41]	  capable	  of	  activating	  both	  LXRs	  isoforms.	  T0901317	  is	   less	  
specific	  than	  previously	  thought	  since	   it	  can	  also	  activate	  the	  bile	  acid	  receptor,	  Farnesoid	  X	  
Receptor	  (FXR)	  even	  more	  potently	  than	   its	  natural	   ligand	  chenodeoxycholic	  acid	  [42]	  and	   it	  
may	  act	  as	  an	  activator	  even	  of	  the	  Pregnane	  X	  Receptor	  (PXR)	  at	  the	  same	  concentrations	  at	  
which	   it	  activates	  LXRs	  [43].	  Therefore	  at	  present	  GW3965	  appears	  to	  be	  the	  most	  selective	  
synthetic	  LXR	  ligand.	  
Recently,	   members	   of	   the	   Proton	   Pump	   Inhibitor	   (PPI)	   family,	   such	   as	   lansoprazole,	  
pantoprazole	   and	  omeprazole,	  have	  been	  described	  as	   LXR	  activators	   in	   several	   cell	   culture	  
systems	   including	   primary	   mouse	   glial	   cells.	   The	   stimulatory	   effect	   of	   these	   PPIs	   on	   LXR	  
transcription	  of	  LXR-­‐regulated	  genes	  was	  abolished	  in	  LXRα-­‐/-­‐β-­‐/-­‐	  glial	  cells	  [44].	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In	  terms	  of	  selective	  ligands,	  a	  subset	  of	  natural	  bile	  acids	  has	  been	  reported	  to	  activate	  LXRα	  
[30]	  whereas	  N-­‐acylthiadiazolines	  have	  selectivity	  for	  LXRβ	  but	  with	  modest	  potency	  [45].	  
	  
1.2.3 Mechanism	  of	  action	  
LXRs	  have	  been	  shown	   to	   regulate	  gene	   transcription	   through	   two	  different	  mechanisms	  of	  
action:	  direct	  activation	  and	  transrepression	  (Figure	  2).	  
	  
1.2.3.1 Direct	  gene	  activation	  
LXRs	  form	  obligate	  heterodimers	  with	  the	  Retinoid	  X	  Receptor	  (RXR)	  [19]	  and	  bind	  to	  specific	  
nucleotide	  sequences	  called	  LXR-­‐responsive	  elements	  (LXREs)	  consisting	  of	  a	  direct	  repeat	  of	  
the	   core	   sequence	   5’-­‐AGGTCA-­‐3’	   separated	   by	   4	   nucleotides	   (DR4)	   [46]	   in	   DNA	   of	   target	  
genes.	  Inverted	  repeat	  of	  the	  same	  sequence	  with	  no	  space	  region	  (IR-­‐0)	  or	  with	  1	  bp	  spacer	  
(IR-­‐1)	  have	  also	  been	  shown	  to	  mediate	  LXR	  transactivation	  [47,	  48].	  
In	  the	  absence	  of	  ligands,	  LXRs	  are	  in	  a	  non-­‐active	  state,	  binding	  to	  cognate	  LXREs	  in	  complex	  
with	  corepressors	  such	  as	  the	  Nuclear	  Receptor	  Corepressor	  (NCoR)	  or	  the	  Silencing	  Mediator	  
of	   Retinoic	   Acid	   and	   Thyroid	   Hormone	   Receptor	   (SMRT)	   [49,	   50].	   The	   binding	   of	   ligands	  
induces	   a	   change	   in	   the	   conformation	   of	   LXRs	   that	   enables	   the	   release	   of	   corepressors,	  
recruitment	  of	  coactivators	  [51]	  and	  in	  turn	  the	  direct	  activation	  of	  gene	  transcription.	  Several	  
coactivators	  have	  been	  described	  for	  LXRs	  .	  These	  include:	  	  Peroxisome	  Proliferator	  Activator	  
Receptor-­‐γ	   (PPARγ)	   coativator-­‐1α	   (PGC-­‐1α)	   [52],	   the	   Steroid	   Receptor	   Coactivator-­‐1	   (SRC-­‐1)	  
[53]	  and	  the	  Activating	  Signal	  Cointegrator-­‐2	  (ASC-­‐2)	  [54].	  
	  
1.2.3.2 Transrepression	  
Due	   to	   transrepression,	   LXRs,	   in	   particular	   LXRβ	   [55]	   exert	   a	   strong	   inhibition	   on	   the	  
transcription	  of	  NF-­‐kB	  regulated	  proinflammatory	  genes	  [56]	  that	  lack	  a	  direct	  binding	  site	  for	  
LXRs.	  After	  binding	  of	  the	   ligand,	  LXRβ	  undergoes	  a	  specific	  SUMOylation	  by	  SUMO-­‐2/3	  that	  
promotes	   interaction	   with	   GPS2,	   a	   subunit	   of	   the	   N-­‐CoR	   complex.	   In	   this	   setting	   the	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dissociation	  of	   the	  N-­‐CoR	  complex	   from	  NF-­‐kB	   is	  prevented	  and	   in	   turn	   the	   transcription	  of	  








Figure	   2.	   LXRs	   influence	   gene	   expression	   by	   (i)	   directly	   promoting	   gene	   transcription	  
after	   heterodimerization	   with	   RXR,	   binding	   with	   the	   ligands	   and	   interaction	   with	  
coactivators	   and	   (ii)	   by	   transrepressing	  NF-­‐kB	   regulated	  genes	  after	   SUMOylation	  and	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1.2.4 Nuclear	  Receptors	  influencing	  LXR	  activity	  
As	   described,	   LXR	   transcriptional	   activities	   are	   the	   result	   of	   a	   complex	   balance	   between	  
bioavailability	  of	  ligands	  and	  their	  related	  metabolizing/catabolizing	  enzymes,	  the	  presence	  of	  
coactivators	   and	   corepressors,	   the	   SUMOylation	   process	   and	   even	   the	   influence	   of	   other	  
nuclear	  receptors	  such	  as	  PPARγ	  and	  Small	  Hetherodimer	  Partner	  (SHP).	  
Indeed	  PPARγ,	  a	  nuclear	  receptor	  activated	  by	  fatty	  acids	  as	  well	  as	  their	  oxidized	  metabolites,	  
has	  been	  shown	  to	  induce	  the	  expression	  of	  LXRα	  in	  macrophages	  [57].	  Furthermore,	  SHP,	  a	  
direct	  target	  gene	  of	  FXR,	   is	  capable	  of	   interacting	  with	  LXRα	  and	  blocking	  its	  transcriptional	  
activity	  [58].	  In	  the	  liver,	  SHP	  is	  one	  of	  the	  main	  effectors	  of	  the	  negative	  feedback	  regulation	  
on	  CYP7A1,	  the	  rate	  limiting	  enzyme	  in	  the	  bile	  acid	  synthesis	  pathway	  [59].	  
Moreover,	   in	   adipose	   tissue,	   LXRα	   transcriptional	   activity	   appears	   to	   be	   estrogen-­‐regulated	  
and,	   in	   the	   LXRα	   promoter,	   a	   sequence	   that	   is	   negatively	   regulated	   by	   estrogens	   has	   been	  
identified	  [60].	  
	  
1.2.5 LXR	  in	  metabolic	  control	  
 
1.2.5.1 Cholesterol	  homeostasis	  
LXRs	  act	  as	  “sterol	  sensors”:	  oxysterols	  activate	  LXRs	  and	  thus	  increase	  transcription	  of	  genes	  
involved	  in	  cholesterol	  catabolism	  and	  excretion.	  
In	   the	   liver,	   LXR	   activation	   promotes	   cholesterol	   elimination	   by	   inducing	   the	   expression	   of	  
CYP7A1,	  the	  rate	  limiting	  enzyme	  in	  the	  classical	  pathway	  of	  bile	  acid	  biosynthesis	  [61],	  as	  well	  
as	   the	   expression	   of	   the	   ATP-­‐binding	   cassette	   transporters,	   ABCG5/G8	   that	   transport	  
cholesterol	   from	   the	   hepatocytes	   into	   the	   bile	   canaliculi	   [62].	   Indeed	   LXRα-­‐/-­‐	   mice	   fed	   a	  
normal	  diet	  have	  normal	  hepatic	  cholesterol	  levels	  [51,	  63,	  64]	  but	  a	  decreased	  bile	  acid	  pool.	  
Administration	  of	  2%	  cholesterol	  diet	  to	  LXRα-­‐/-­‐	  mice	  clearly	  shows	  their	  inability	  to	  eliminate	  
cholesterol	   by	   its	   conversion	   to	   bile	   acids	   with	   a	   consequent	   accumulation	   of	   cholesterol	  
esters	  in	  the	  liver	  [51,	  64].	  Surprisingly,	  on	  the	  same	  diet,	  LXRβ-­‐/-­‐	  mice	  have	  a	  similar	  response	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as	  WT	  mice:	  hepatic	  cholesterol	   levels	  are	  normal	  as	  well	  as	   the	  expression	  of	   the	  enzymes	  
involved	   in	  bile	  acid	  metabolism	  (CYP7A1,	  CYP7B,	  CYP8B1,	  CYP27)	  [63]	   indicating	  that	  of	  the	  
two	  LXRs	   it	   is	  LXRα	  which	  controls	   liver	  cholesterol	  balance.	  LXRs	  also	  protects	  extrahepatic	  
tissues	  from	  cholesterol	  accumulation.	  The	  main	  mechanism	  of	  this	  protection	  is	  through	  the	  
control	  of	  cholesterol	  reverse	  transport.	  In	  macrophages,	  LXR	  agonists	  induce	  the	  expression	  
of	   ABCA1,	   ABCG1	   and	   ABCG4	   transporters	   that	   promote	   the	   efflux	   of	   cholesterol	   to	   high	  
density	  lipoproteins	  (HDL)	  [65,	  66].	  The	  observed	  accumulation	  of	  foam	  cells	  rich	  in	  cholesterol	  
esters,	   in	   the	   aorta,	   spleen,	   and	   lung	   of	   LXRα-­‐/-­‐β-­‐/-­‐	   mice	   is	   thought	   to	   be	   a	   result	   of	   an	  
impaired	  reverse	  cholesterol	  transport	  [64].	  
	  
1.2.5.2 Fatty	  acid	  metabolism	  
The	  study	  of	  LXR	  knock-­‐out	  mice	  also	  gave	  important	  insights	  into	  LXR	  physiology	  and	  the	  role	  
of	  LXRs	  in	  fatty	  acid	  metabolism.	  Indeed	  liver	  triglycerides	  are	  significantly	  reduced	  in	  LXRα-­‐/-­‐
β-­‐/-­‐	  mice	   [63]	   and	   treatment	  with	   LXR-­‐agonist	   leads	   to	  development	  of	  hepatic	   steatosis	   in	  
WT	  mice	   [41]	  as	  a	  consequence	  of	  an	  upregulation	  of	  genes	   involved	   in	   fatty	  acid	  synthesis	  
(scd1,	  fas,	  srebp-­‐1c).	  
	  
1.2.5.3 Glucose	  homeostasis	  
	  A	  role	  for	  LXRs	   in	  controlling	  glucose	  homeostasis	  has	  been	  demonstrated	  in	  several	  animal	  
models.	   Treatment	   of	   diabetic	  mice	   and	   Zucher	   rats	  with	   an	   LXR	   agonist	   is	   associated	  with	  
improvement	   of	   glucose	   tolerance	   and	   decrease	   in	   gluconeogenesis	   [67,	   68].	   In	   parallel,	   in	  
adipose	   tissue,	   LXRs	   positively	   control	   the	   expression	   of	   the	   insulin-­‐dependent	   glucose	  
transporter	  4	  (GLUT4)	  [69]	  that	  mediates	  the	  uptake	  of	  glucose	  from	  peripheral	  blood.	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1.2.6 LXRs	  in	  inflammatory	  response	  
Besides	   the	  previously	  described	  metabolic	   actions,	   there	   is	   emerging	  evidence	   that	   LXR,	   in	  
particular	   LXRβ	   [55],	   may	   act	   as	   key	   effectors	   in	   the	   integration	   between	   lipid	   and	  
inflammatory	  signals,	  both	  in	  vitro	  and	  in	  vivo.	  
In	  peritoneal	  and	  bone	  marrow-­‐derived	  macrophages,	  pre-­‐treated	  with	  LXR	  agonists,	  there	  is	  
reduced	  expression	  of	   inflammatory	   genes	   in	   response	   to	  bacterial	   pathogens	   as	  well	   as	   to	  
stimulation	   with	   LPS,	   TNFα,	   or	   IL-­‐1β.	   This	   effect	   was	   paralleled	   with	   the	   induction	   of	  
cholesterol	   transporters,	   like	   ABCA1	   and	   was	   abolished	   in	   macrophages	   lacking	   both	   LXR	  
isoforms	  [70,	  71].	  The	  profile	  of	  LXR-­‐anti-­‐inflammatory	  action	  is	  defined	  by	  reduced	  inducible	  
Nitric	   Oxide	   Synthase	   (iNOS)	   mRNA,	   protein	   and	   activity;	   inhibition	   of	   COX-­‐2	   protein	  
expression;	  suppression	  of	  numerous	  genes	  involved	  in	  macrophage	  innate	  immune	  response	  
such	   as	   the	   cytokines	   IL-­‐6,	   IL-­‐1β,	   the	   granulocyte-­‐colony	   stimulating	   factor	   (G-­‐CSF),	   the	  
chemokines	   MCP-­‐1,	   MCP-­‐3	   (Monocyte	   Chemoattractant	   Protein),	   the	   Macrophage	  
Inflammatory	  protein-­‐1β	  (MIP-­‐1β)	  [71]	  and	  the	  metalloproteinase	  MMP-­‐9	  [70,	  72].	  
In	  an	  anti-­‐inflammatory	  setting,	  LXRs	  may	  also	  directly	  upregulate	  the	  expression	  of	  Arginase-­‐
II	  gene	  (ArgII)	  in	  macrophages	  [73].	  ArgII	  catalyses	  the	  conversion	  of	  L-­‐arginine	  to	  L-­‐ornithine,	  
therefore	   competing	  with	   iNOS	   for	   the	   common	   substrate	   arginine	   [74]	   leading	   to	   reduced	  
production	  of	  cytotoxic	  NO	  and	  therefore	  reduced	  inflammatory	  activity.	  
Numerous	   in	  vivo	  studies	  strongly	  support	  the	  anti-­‐inflammatory	  action	  of	  LXR-­‐agonists	  both	  
in	   the	   treatment	   and	   prevention	   of	   inflammatory	   diseases,	   including	   atherosclerosis.	   	   LXR	  
clearly	   shows	   a	   double	   role	   by	   regulating	   both	   metabolism	   and	   inflammation	   in	   murine	  
models	  of	  atherosclerosis:	  treatment	  of	  ApoE-­‐/-­‐	  mice	  with	  an	  	  LXR	  agonist	  induces	  a	  reduction	  
in	  serum	  total	  cholesterol	  [72]	  as	  well	  as	  in	  MMP-­‐9	  expression	  in	  the	  aorta	  [71]	  resulting	  in	  a	  
decreased	  area	  of	  atherosclerotic	  lesions.	  
Other	  impressive	  effects	  of	  synthetic	  LXR-­‐agonists	  have	  been	  described	  in	  skin	  where	  topical	  
application	   of	   these	   compounds	   can	   reverse	   both	   atopic	   and	   irritant	   dermatitis	   in	   hairless	  
mice	  [75]	  as	  well	  as	  in	  BL6	  mice	  [71,	  76].	  In	  these	  models,	  edema	  and	  inflammatory	  infiltration	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are	  reduced	  [71,	  76]	  together	  with	   lower	   immunoreactivity	  of	  TNF-­‐α	  and	  IL-­‐1α	   [76].	  Natural	  
LXR	  ligands	  are	  also	  effective	  in	  ear	  dermatitis	  [76],	  as	  well	  as	  in	  irritant	  and	  allergic	  but	  not	  in	  
atopic	   dermatitis	   of	   hairless	   mice	   [75].	   Topical	   treatment	   with	   LXR-­‐agonist	   has	   shown	  
promising	  results	  even	  in	  the	  prevention	  of	  wrinkle	  formation	  in	  a	  mouse	  model	  of	  photoaging	  
[77].	  
Strong	  beneficial	  effects	  of	  LXR	  agonists	  have	  also	  been	  obtained	  in	  the	  CNS.	  In	  murine	  models	  
of	   spinal	  cord	   injury	   [78],	  Alzheimer’s	  disease	   [79],	  acute	  encephalomyelitis	   	   [80]	  and	  global	  
brain	  ischemia	  [81]	  the	  amount	  of	   inflammatory	  infiltrate,	  expression	  of	  cytokines	  as	  well	  as	  
clinical	  outcome	  are	  significantly	  alleviated	  by	  LXR	  agonists.	  
In	  the	  respiratory	  system	  more	  diverse	  actions	  of	  LXR	  agonists	  have	  been	  observed.	  Oral	  pre-­‐
treatment	  with	   LXR	   agonist	   prevents	   severe	   inflammatory	   events	   in	  mice	   undergoing	   nasal	  
instillation	   of	   LPS	   [82,	   83]	   and	   intra-­‐peritoneal	   administration	   of	   LXR	   agonist	   reduces	  
inflammation	   in	   a	   carrageen-­‐induced	   pleurisy	   [84].	   On	   the	   other	   hand,	   murine	   models	   of	  
allergy	   and	   asthma	   display	   an	   increased	   airway	   reactivity	   and	   bronchial	   smooth	   muscle	  
thickness	  [85]	  from	  high	  doses	  of	  LXR	  agonist.	  
Different	  effects	  of	  LXR	  agonists	  are	  also	  seen	  in	  murine	  collagen-­‐induced	  arthritis:	  increased	  
articular	   inflammation	   and	   cartilage	   destruction	   have	   been	   described	   as	   adverse	   events	   of	  
both	  GW	  and	  T0901317	  given	   ip	   [86]	  at	  a	  dose	  of	  10-­‐30	  mg/Kg	   for	  6	  days.	  However,	   lower	  
doses	   of	   GW3965	   (0.1-­‐1	   mg/Kg)	   have	   been	   shown	   to	   improve	   arthritis,	   clinically,	  
histopathologically	  and	  in	  reducing	  pro-­‐inflammatory	  cytokines	  [87].	  
These	   discrepancies	   may	   in	   part	   be	   explained	   by	   the	   fact	   that	   high	   doses	   of	   LXR	   agonist	  
administered	  during	  a	  relatively	  long	  period	  of	  time	  could	  exert	  an	  antagonistic	  effect	  on	  LXR	  
as	  described	  by	  ourselves	  [88]	  and	  others	  [72].	  Even	  the	  route	  of	  administration,	  the	  property	  
of	   the	  solvent,	   the	  severity	  of	   the	  pre-­‐existing	  disease	  as	  well	  as	  sex	  and	  age	  of	   the	  animal,	  
may	   affect	   the	   pharmacological	   properties	   of	   LXR	   agonists	   in	   vivo	   and,	   therefore,	   explain	  
opposite	   effects	   of	   the	   same	   compound.	   More	   pharmacokinetic	   and	   pharmacodynamic	  
studies	  are	  required	  for	  a	  safe	  anti-­‐inflammatory	  use	  of	  synthetic	  LXR	  ligands.	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Mechanistically,	   the	   described	   anti-­‐inflammatory	   action	   of	   LXR	   is	   exerted	   through	   a	  
transrepression	   on	   the	   activity	   of	   the	   pro-­‐inflammatory	   transcription	   factor	  NF-­‐kB	   [71]	   that	  
has	  been	  discussed	  above	  (Figure	  2)	  [55,	  56].	  
Moreover,	   in	  the	  scenario	  of	  a	  crosstalk	  between	  metabolism	  and	  inflammation,	   it	  has	  been	  
reported	  that	  infectious	  agents,	  like	  bacteria	  or	  viruses,	  inhibit	  LXR	  signaling	  by	  activating	  Toll	  
Like	  Receptor	  3	  (TLR3)	  and	  TLR4	  in	  cultured	  macrophages	  as	  well	  as	  in	  aortic	  tissue	  in	  vivo	  [70].	  
Even	   with	   the	   activation	   of	   both	   LXR	   and	   TLR3/4,	   cholesterol	   efflux	   from	   macrophage	   is	  
markedly	   decreased.	   It	   appears	   that	   the	   interferon	   regulatory	   factor	   3,	   IRF	   3	   may	   be	   the	  
mediator	  of	  the	  repression	  of	  LXR	  activity	  [70].	  
	  
1.2.7 LXRs	  in	  cell	  cycle	  control	  
Antiproliferative	  and	  pro-­‐apoptotic	  effects	  of	  LXR	  activation	  have	  been	  described	  in	  a	  wide	  set	  
of	   cell	   culture	   systems	   ranging	   from	  primary	   pancreatic	  β-­‐cells	   to	   breast,	   ovarian,	   prostate,	  
stomach,	  and	  liver	  tumor	  cell	  lines.	  
In	   pancreatic	   islets	   and	   β-­‐cell	   cultures,	   where	   both	   LXRα	   and	   LXRβ	   are	   expressed	   with	   a	  
prevalence	  of	  LXRβ	  [89,	  90],	  treatment	  with	  an	  LXR	  agonist	  (T0901317)	  decreases	  the	  rate	  of	  
cell	  proliferation	  in	  a	  dose-­‐dependent	  manner	  starting	  from	  5	  µmol/l	  for	  48	  h	  [90].	  At	   lower	  
doses	  (1-­‐2	  µmol/l),	  LXR-­‐agonist	  exerts	  the	  antiproliferative	  activity	  only	  in	  the	  presence	  of	  the	  
RXR	  agonist	  9-­‐cis-­‐retinoic	  acid	  [91].	  The	  mechanism	  underlying	  this	  cell	  cycle	  arrest	  in	  Go/G1	  
phase	  following	  LXR	  activation	  is	  still	  not	  completely	  understood.	  An	  increase	  in	  p27	  protein	  
level	   has	   been	   described	   as	   a	   possible	   responsible	   mechanism	   and	   evidence	   for	   this	   is	  
supported	  by	  the	  ability	  of	  p27	  siRNA	  to	  prevent	  the	  effect	  of	  LXR	  on	  cellular	  proliferation	  [91].	  
In	  addition,	  a	  proapoptotic	  effect	  of	  LXR-­‐agonist	  has	  been	  shown	  in	  pancreatic	  islets	  and	  β-­‐cell	  
cultures	   [90-­‐92],	   together	   with	   an	   increased	   lipogenic	   activity	   (due	   to	   an	   activation	   of	   LXR	  
target	   genes,	  ADD,	   FAS,	  ACC)	   resulting	   in	   intracellular	   high	   levels	   of	   TG	  and	   free	   fatty	   acids	  
[92].	  This	  observation	  may	   indicate	  that	  the	  pro-­‐apoptotic	  effect	  of	  LXR	   is	  due	  to	  a	   lipotoxic	  
damage	  [93].	   	   Indeed	  in	  several	  cell-­‐systems	  obtained	  from	  prostatic	  tissue	  (RWPE1,	  LNCaP),	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stomach	  cancer	   (SNU16)	  and	  hepatocellular	  carcinoma	  (HepG2),	  LXR-­‐agonist	   (T0901317	  and	  
GW3965)	  induces	  lipogenic	  genes	  (SREBP-­‐1c,	  FAS),	  increases	  levels	  of	  TG	  and	  FFA	  and	  arrests	  
the	  cell	  cycle	   in	  G0/G1	  phase	  [93].	  These	  effects	  are	  markedly	  reduced	  after	  knock-­‐down	  of	  
FAS	  with	  siRNA.	  
In	  a	  more	  complex	  interplay	  involving	  also	  androgen	  signaling,	  LXRs	  participate	  in	  the	  control	  
of	  prostate	  cancer	  cell	  proliferation.	  Both	  synthetic	  (T0901317)	  and	  natural	  ligands	  (22(R)-­‐HC	  
and	   24(S)-­‐HC)	   are	   effective	   in	   inhibiting	   cell	   growth	   in	   particular	   in	   androgen-­‐independent	  
LNCaP	  cells	  [94]	  both	  in	  vitro	  and	  in	  vivo.	  Indeed,	  in	  athymic	  nude	  mice,	  LXR	  agonist	  treatment	  
inhibited	   the	   growth	   of	   LNCaP	   tumor	   xenografts	   [94]	   and	   delayed	   the	   progression	   to	  
androgen-­‐independent	   tumors	   [95].	   Although	   the	   mechanism	   of	   action	   is	   still	   unknown,	   it	  
should	  be	  noted	  that	  T0901317	  may	  act	  as	  competitive	  antagonist	  on	  androgen	  receptor	  [96].	  
Nevertheless,	  in	  vivo	  role	  of	  LXRs,	  in	  particular	  LXRα,	  in	  prostate	  pathophysiology	  is	  supported	  
by	  studies	  in	  LXRα-­‐/-­‐	  mice	  in	  which	  the	  ventral	  prostate	  is	  affected	  by	  a	  smooth-­‐muscle	  actin-­‐
positive	   stromal	   overgrowth	   [88].	  Mechanistically,	   the	   transforming	   growth	   factor	  β	   (TGFβ)	  
signaling	  seems	  to	  be	  involved	  since	  the	  expression	  of	  snail	  and	  smad-­‐2/3,	  downstream	  genes	  
of	  TGFβ,	  was	  markedly	  increased	  in	  the	  ventral	  prostate	  of	  LXRα-­‐/-­‐	  mice	  [88].	  
	  
1.2.8 LXRs	  in	  embryogenesis	  
Studies	  from	  our	  own	  laboratory	  have	  demonstrated	  that	  LXRβ	  has	  an	  important	  role	  
in	  the	  development	  of	  cerebral	  cortex.	  At	  late	  stage	  of	  embryogenesis	  (E	  18.5)	  and	  in	  neonates	  
(P2),	   LXRβ-­‐/-­‐	  mice	   have	   a	   smaller	   brain	   with	   a	   reduction	   in	   the	   number	   of	   neurons	   in	   the	  
superficial	   cortical	   layers.	   During	   development,	   neurons	   migrate	   from	   lower	   layers	   to	  
superficial	   layers.	  After	  birth	   (P2),	   in	  LXRβ-­‐/-­‐	  mice	   the	  number	  of	  neurons	   is	  higher	   in	   lower	  
cortical	   layers	   (IV)	  while	   in	  WT	  mice	  more	  neurons	  are	   in	   the	  upper	   layer	   (II-­‐III)	   indicating	  a	  
migration	  defect	  [28].	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1.2.9 LXRs	  genetics	  in	  human	  diseases	  
The	   role	   of	   genetic	   mutations	   or	   gene	   polymorphisms	   of	   LXRs	   in	   human	   diseases	  
corresponding	  to	  the	  phenotypes	  described	  in	  the	  transgenic	  animals	  is	  relatively	  unexplored;	  
at	  the	  moment	  only	  three	  such	  studies	  have	  been	  published.	  
Several	  single	  nucleotide	  polymorphisms	  (SNPs)	  of	  LXRβ	  (chromosome	  19)	  have	  been	  
identified:	   LXR1	   in	   intron	   5,	   LXR2	   in	   intron	   7,	   LXR3	   in	   the	   3´UTR	   and	   LXR4	   in	   intron	   2.	   An	  
association	  between	  the	  risk	  of	  developing	  late-­‐onset	  (age	  at	  onset	  after	  60	  years)	  Alzheimer	  
disease	   and	   LXR2	   and	   LXR4	   has	   been	   shown	   in	   an	   American	   population	   of	   931	   Alzheimer	  
disease	  patients	  [97].	  Although	  LXR2	  seems	  to	  be	  a	  silent	  SNP,	  LXR4	  is	  likely	  to	  be	  functional,	  
residing	  in	  either	  a	  coding	  region	  or	  in	  a	  splicing	  junction.	  Moreover,	  this	  association	  has	  been	  
confirmed	  in	  a	  Spanish	  population	  of	  414	  Alzheimer	  disease	  patients.	  In	  this	  study	  there	  was	  
an	   increased	   risk	   if	   these	   SNPs	   (LXR2,	   LXR4,	   LXR1)	   are	   associated	   with	   a	   SNP	   in	   heme-­‐
oxygenase-­‐1	  (413	  TT)	  [98].	  
The	   third	   study	   involves	   a	   Swedish	   population	   of	   559	   obese	   patients.	   This	   study	  
revealed	  that	  one	  LXRα	  (rs2279238)	  and	  two	  LXRβ	  SNPs	  (LB44732G>A	  and	  rs2695121),	  in	  the	  
promoter	  region	  and	  in	  intron	  2,	  are	  associated	  with	  obesity	  [99].	  
More	   studies	   are	   required	   to	   confirm	   that	   these	   SNPs	  have	   a	   functional	   role	   in	   the	  
susceptibility	  to	  Alzheimer	  disease	  and	  obesity.	  
	  
1.3 AMYOTROPHIC	  LATERAL	  SCLEROSIS	  
Amyotrophic	   lateral	   sclerosis	   (ALS)	   is	   an	   adult-­‐onset	   neurodegenerative	   disorder	  
characterized	  by	  progressive	  loss	  of	  motor	  neurons	  in	  the	  spinal	  cord,	  in	  the	  cortex	  and	  in	  the	  
brain	  stem.	  The	  worldwide	  prevalence	  of	  ALS	  is	  4-­‐6	  per	  100,000	  inhabitants	  with	  an	  incidence	  
of	  0.5-­‐3	  per	  100,000	  yearly	  [100].	  	  Approximately	  10%	  of	  ALS	  cases	  are	  familial	  (FALS)	  with	  a	  
genetic	  autosomal	  dominant	  trait,	  while	  the	  remaining	  90%	  of	  cases	  are	  sporadic	  (SALS)	  [101].	  
In	  familial	  cases,	  the	  prevalence	  of	  affected	  males	  is	  much	  higher	  (male:female	  ratio	  7:1)	  but	  
this	   gender	  difference	   is	   reduced	   	  by	   increasing	  age	  of	  presentation,	   reaching	  a	  1:1	   ratio	   in	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patients	  in	  their	  eighth	  decade	  [100,	  101].	  Typically	  this	  disease	  is	  fatal	  within	  3-­‐5	  years	  of	  the	  
onset	  of	  symptoms.	  
Clinically,	  FALS	  and	  SALS	  are	  indistinguishable	  but	  a	  distinct	  manifestation	  associated	  
with	  parkinsonism-­‐dementia,	  called	  PD	  Complex	  (PDC)	  is	  seen	  in	  the	  pacific	  islands	  of	  Guam.	  
In	  the	  indigenous	  Chamorro	  population	  of	  this	  island,	  the	  prevalence	  of	  ALS	  is	  strongly	  higher	  
than	   elsewhere	   in	   the	   world	   with	   a	   more	   malignant	   clinical	   appearance	   [102].	   The	  
etiopathogenesis	   of	   PDC	   is	   still	   unknown	   but	   both	   genetic	   and	   environmental	   factors	   are	  
thought	   to	   be	   involved.	   The	   characteristic	   pathological	   finding	   at	   autopsy	   is	   the	   high	  
prevalence	  of	  neurofibrillary	  tangles	  (NFTs)	  in	  patients	  with	  PDC.	  	  Interestingly,	  in	  comparison	  
with	   control	   American	   subjects,	   healthy	   Chamorros	   also	   have	   an	   increase	   in	   neurofibrillary	  
tangles	  [103].	  
Leucine-­‐rich	  repeat	  kinase	  2	  (LRRK-­‐2),	  a	  protein	  mutated	  in	  familial	  Parkinson	  disease	  
with	   unclear	   function,	   has	   been	   shown	   to	   accumulate	   in	   these	   tangles	   and	   TDP-­‐43,	   a	  
transcriptional	   repressor	   normally	   expressed	   in	   the	   nucleus,	   accumulates	   in	   glial	   inclusions	  
[104].	  One	  interesting	  hypothesis	  on	  the	  role	  of	  diet	  in	  the	  etiology	  of	  ALS	  involves	  the	  chronic	  
exposure	   to	   toxins	   from	   Cycas	   micronesica.	   This	   is	   a	   palm	   from	   which	   the	   flour	   has	  
traditionally	   been	   prepared	   and	   used	   as	   the	   major	   source	   of	   flour	   when	   wheat	   is	   scarce.	  
Feeding	  of	  monkeys	  with	  up	  to	  2	  g	  of	  cycad	   flour	  does	  not	   lead	  to	  any	  neurological	  disease	  
[105].	   Thus	   it	   is	   thought	   that	   the	   indigenous	  Guam	  population	   has	   a	   genetic	   predisposition	  
which	  renders	  them	  susceptible	  to	  the	  toxic	  effects	  of	  cycad	  flour.	  
Still	   unknown	   is	   also	   the	  pathogenesis	   of	   the	  pure	   sporadic	   form	  of	  ALS.	   In	   familial	  
cases	  a	  mutation	  of	  SOD1	  gene	  has	  been	  described	  [106].	  SOD1	  is	  a	  Cu/Zn-­‐binding	  superoxide	  
dismutase	  that	  catalyzes	  the	  dismutation	  of	  toxic	  superoxide	  anion	  O2
-­‐	  to	  O2	  and	  H2O2	  [107].	  
The	  hypothesis	  is	  that	  in	  FALS	  patients	  the	  activity	  of	  SOD1	  could	  be	  either	  reduced,	  leading	  to	  
an	  accumulation	  of	  toxic	  superoxide	  radicals	  or,	  more	  probably,	  increased	  leading	  to	  excessive	  
levels	   of	  H2O2	   that	   can	   react	  with	   some	  metals	   like	   iron	   and	   generate	  highly	   toxic	   hydroxyl	  
radicals	  [108].	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1.4 MALABSORPTION	  SYNDROME	  
Malabsorption	   syndrome	   is	   a	   clinical	   condition	   characterized	   by	   a	   combination	   of	  
symptoms	  like	  weight	  loss	  or	  growth	  failure	  in	  children,	  steatorrhoea,	  diarrhea,	  and	  anaemia	  
which	   result	   from	   unsuccessful	   nutrient	   absorption	   from	   the	   diet.	   Numerous	   diseases	   are	  
responsible	  for	  this	  syndrome	  and	  according	  to	  their	  etiology,	  they	  can	  be	  classified	  into	  three	  
groups:	  (a)	  alterations	  of	  the	  digestive	  process	  due	  to	  deficit	  of	  enzymes	  and	  bile	  acids	  such	  as	  
in	  chronic	  pancreatitis,	  cystic	   fibrosis,	  and	  cholestatic	   liver	  diseases;	   (b)	  alterations	   in	  uptake	  
and	  transport	  due	  to	  a	  damage	  of	  absorptive	  surface	  such	  as	  in	  celiac	  disease,	  Crohn´s	  disease,	  
and	   autoimmune	   enteropathy;	   (c)	   microbial	   causes	   such	   as	   bacterial	   overgrowth	   and	  
parasitosis	   [109].	   The	  major	   cause	  of	   defective	   intraluminal	   digestion	   is	   pancreatic	   exocrine	  
insufficiency	   due	   to	   chronic	   pancreatitis	   and	   cystic	   fibrosis.	   In	   industrialized	   countries,	   the	  
incidence	  of	  chronic	  pancreatitis	  is	  between	  3.5-­‐10	  per	  100.000	  inhabitants.	  About	  70-­‐80	  %	  of	  
cases	   are	   related	   to	   long-­‐term	   alcohol	  misuse	   while	   10-­‐30	   %	   of	   cases	   represent	   idiopathic	  
pancreatitis	   for	   which	   the	   etiology	   is	   still	   unknown	   [110].	   A	   large	   number	   of	   mutations	   in	  
genes	   coding	   for	   serine	   protease	   inhibitor,	   SPINK1,	   or	   the	   cystic	   fibrosis	   transmembrane	  
conductance	  regulator,	  CFTR,	  have	  been	  described	  to	  be	  involved	  not	  only	  in	  the	  pathogenesis	  
of	  pancreatitis	  but	  also,	  working	   in	  concert	  with	  other	  genetic	  and	  environmental	   factors,	   in	  
the	  susceptibility	  to	  this	  disease	  [111].	  Moreover,	  in	  humans,	  it	  has	  been	  shown	  that	  genetic	  
polymorphisms	  of	  genes	  regulating	  the	  inflammatory	  response,	  like	  heat	  shock	  protein	  70-­‐2	  or	  
tumor	  necrosis	  factor	  α,	  are	  associated	  with	  an	  increased	  risk	  of	  acute	  pancreatitis	  [112].	  
	  
1.5 GALLBLADDER	  CANCER	  
Carcinoma	   of	   the	   gallbladder	   is	   a	   highly	   fatal	   and	   aggressive	   disease	   with	   a	   poor	  
prognosis.	   It	   is	   the	  most	   common	  malignant	   tumor	  of	   the	  biliary	   tract	  with	  5000	  estimated	  
new	  cases	  per	  year	  in	  United	  States	  [113].	  Incidence	  of	  gallbladder	  carcinoma	  varies	  with	  sex	  
and	  ethnicity.	  Women	  are	  affected	  two	  to	  six	  times	  more	  than	  men	  and	  the	  highest	  incidences	  
  17 
are	  reported	  in	  Native	  Americans,	  South	  American	  populations,	  people	  from	  Poland	  and	  North	  
of	  India	  [114].	  
The	   etiology	   of	   gallbladder	   carcinoma	   involves	   a	   complex	   interplay	   between	  
hormones,	   metabolic	   alterations,	   infections	   and	   even	   anatomical	   anomalies	   [115].	  
Epidemiological	   studies	   have	   shown	   a	   strong	   association	   of	   this	   tumor	   (in	   particular	   the	  
squamous	   and	   adenosquamous	   variant)	   with	   cholesterol	   gallstone	   disease	   [116]	   and	   with	  
many	  of	  its	  risk	  factors	  like	  obesity,	  high	  carbohydrate	  intake	  and	  female	  sex	  [117].	  The	  strong	  
female	   incidence	   has	   raised	   the	   hypothesis	   that	   estrogens	   could	   play	   an	   important	  
pathophysiological	   role	   in	   the	   development	   of	   gallbladder	   cancer.	   It	   has	   been	   shown	   that	  
Hormone	  Replacement	  Therapy	  in	  postmenopausal	  women	  significantly	   increases	  the	  risk	  of	  
gallbladder	  diseases	  [118,	  119].	  Interestingly,	  this	  risk	  is	  lower	  with	  a	  transdermal	  therapy	  that	  
with	  oral	  therapy	  [120].	  
In	  2004	  Sumi	  et	   al.	   [121]	   reported	   that	  Estrogen	  Receptor	  β	   (ERβ)	  expression	  was	  
significantly	   reduced	   in	   the	   cancerous	   regions	   of	   gallbladder	   cancers	   and	  was	   completely	  
lost	   at	   the	   invasive	   front.	   Loss	   of	   ERβ	   was	   associated	   with	   malignant	   properties	   of	   the	  
primary	   tumor	   such	   as	   lymph	   node	   metastasis,	   advanced	   stage,	   lower	   differentiation	   of	  
histological	  type,	  lymphatic	  invasion	  and	  a	  poor	  prognosis	  of	  the	  patients.	  ERβ	  is	  the	  nuclear	  
receptor	   which	   has	   antiproliferative	   actions	   in	   many	   animal	   models	   including	   cancer	   cell	  
lines	  [122,	  123]	  and	  tumor	  xenographs	  [124,	  125].	  
Very	  little	  is	  known	  about	  the	  molecular	  and	  genetic	  pathways	  of	  gallbladder	  cancer.	  
Unlike	   in	  many	  other	  cancers,	  Ras	  and	  p53	  genes	  do	  not	  appear	  to	  cooperate	   in	  gallbladder	  
cancer	   [126],	   while	   the	   cyclin-­‐dependent	   kinase	   4	   inhibitors	   p16Ink4/CDKN2,	   p16Ink4	   and	  
p15Ink4B	  are	  involved	  [127].	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2 AIMS	  OF	  THE	  THESIS 
The	  overall	  aim	  of	  this	  thesis	  is	  to	  determine	  the	  specific	  and	  distinct	  roles	  of	  LXRβ	  by	  studying	  
the	  phenotype	  of	  LXRβ-­‐/-­‐	  mice	  in	  comparison	  with	  LXRα-­‐/-­‐	  and	  LXRα-­‐/-­‐β-­‐/-­‐	  mice.	  
	  
2.1 PAPER	  I	  
As	  described	  previously	  [128,	  129],	  by	  the	  age	  of	  7	  months,	  LXRβ-­‐/-­‐	  male	  mice	  are	  affected	  by	  
a	  progressive	  death	  of	  big	  motor	  neurons	  in	  the	  latero-­‐ventricular	  horn	  of	  the	  spinal	  cord.	  
β-­‐sitosterol,	  a	  compound	  structurally	   similar	   to	  cholesterol,	  has	  been	  shown	  to	   increase	   the	  
expression	  of	  LXR	  target	  genes	  [39].	  β-­‐sitosterol	  is	  known	  to	  be	  toxic	  to	  motor	  neurons	  and	  it	  
is	  also	  thought	  to	  be	  one	  of	  the	  environmental	  factors	  that	  in	  concert	  with	  unknown	  genetic	  
predispositions	  could	  lead	  to	  the	  ALS-­‐PDC	  in	  Guam	  population	  [130].	  
Aim	  of	  this	  study	  was	  to	   investigate	  the	  possible	  toxicity	  of	  β-­‐sitosterol	   in	  LXRβ-­‐/-­‐	  mice	  with	  
particular	  attention	  to:	  
• Motor	  coordination;	  
• Intestinal	  expression	  of	  ABCG5,	  ABCG8	  transporters;	  
• Histopathology	  of	   spinal	   cord	  and	   substantia	  nigra,	   two	  areas	   involved	   in	  ALS-­‐PCD	  
complex;	  
• Cholesterol	  levels	  in	  brain	  and	  serum.	  
	  
2.2 PAPER	  II	  
As	  previously	  discussed,	  LXRβ-­‐/-­‐	  mice	  demonstrate	  a	  reduction	  in	  the	  size	  of	  perigonadal	  fat	  
pad	  that	  is	  characterized	  by	  smaller	  adipocytes,	  compared	  to	  WT	  mice	  [63].	  LXRβ-­‐/-­‐	  mice	  are	  
thinner	  and	  resistant	  to	  weight	  gain	  when	  fed	  with	  a	  diet	  containing	  a	  high	  amount	  of	  fat.	  A	  
similar	   phenotype	   has	   also	   been	   described	   in	   LXRα-­‐/-­‐β-­‐/-­‐	   mice	   but	   not	   in	   LXRα-­‐/-­‐	   mice	  
indicating	  a	  specific	  role	  of	  LXRβ	  in	  controlling	  body	  weight	  [63,	  131,	  132].
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Malabsorption	  syndrome	  is	  a	  clinical	  condition	  characterized	  by	  weight	  loss	  or	  growth	  failure	  
in	  children	  that	  results	  from	  unsuccessful	  nutrient	  absorption	  from	  the	  diet.	  One	  of	  the	  main	  
causes	  of	  malabsorption	  syndrome	  is	  a	  pancreatic	  exocrine	  insufficiency	  [109].	  
Aim	  of	  this	  study	  was	  to	  investigate	  the	  pathogenesis	  of	  the	  lean	  phenotype	  in	  LXRβ-­‐/-­‐	  mice	  
with	  particular	  attention	  to	  the:	  
• Pancreatic	  exocrine	  function	  (assay	  of	  serum	  amylase,	  lipase,	  fecal	  protease);	  
• Histopathology	  of	  the	  pancreas;	  
• Transmission	  Electron	  Microscopy	  (TEM)	  of	  the	  pancreas.	  
	  
2.3 PAPER	  III	  
According	   to	   the	   findings	   of	   Paper	   II	   (see	   Results	   section),	   the	   water	   channel	   Aquaporin-­‐1	  
(AQP-­‐1)	  appears	  to	  have	  a	  reduced	  expression	  (protein	  and	  mRNA)	  in	  the	  pancreas	  of	  LXRβ-­‐/-­‐	  
mice.	  
The	  gallbladder,	  the	  storage	  organ	  for	  bile,	  is	  one	  of	  the	  most	  active	  water	  transporting	  organs	  
of	   the	   digestive	   system.	   Two	   aquaporins	   have	   been	   identified	   in	   the	   cholangiocytes	   of	   this	  
tissue:	  AQP-­‐1	  and	  AQP-­‐8.	  
Aim	   of	   this	   study	   was	   to	   investigate	   whether	   in	   the	   gallbladder	   of	   LXRβ-­‐/-­‐	   mice	   water	  
transport	  was	  affected	  with	  particular	  attention	  to:	  
• mRNA	  and	  protein	  expression	  of	  AQP-­‐1	  and	  AQP-­‐8	  in	  LXRβ-­‐/-­‐mice;	  
• mRNA	   and	   protein	   expression	   of	   AQP-­‐1	   and	   AQP-­‐8	   in	  WT	  mice	   treated	   with	   LXR	  
agonist;	  
• histopathology	  of	  the	  gallbladders.	  
	  
2.4 PAPER	  IV	  
According	  to	  the	  findings	  in	  Paper	  III	  (see	  Results	  section),	  the	  male	  LXRβ-­‐/-­‐	  mouse	  gallbladder	  
does	  not	   show	  any	  macroscopic	  alterations.	  Gallbladder	  diseases	  are	   two	   to	   six	   times	  more	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frequent	   in	   women	   that	   in	   man	   and	   the	   incidence	   is	   even	   higher	   in	   patients	   undergoing	  
hormonal	  replacement	  therapy	  [118].	  
Aim	   of	   this	   paper	   was	   to	   study	   the	   phenotype	   of	   female	   LXRα-­‐/-­‐,	   LXRβ-­‐/-­‐,	   LXRα-­‐/-­‐β-­‐/-­‐
gallbladders	  in	  particular	  with	  reference	  to:	  
• Histopathology;	  
• Proliferation/cell	  death	  markers;	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3 NOTES	  ON	  METHODOLOGY	  
Material	   and	  methods	   used	   in	   this	   thesis	   are	   fully	   described	   in	   the	   specific	   section	   of	   each	  
paper.	  They	  include:	  
• Knock-­‐out	  animals;	  
• Immunohistochemistry;	  
• Western	  blotting;	  
• RT-­‐PCR	  real	  time;	  
• Cholesterol	  assay	  in	  brain;	  
• Preabsorption	  of	  LXRβ	  anitibody;	  
• Treatment	  of	  mice	  with	  LXRs	  agonists;	  
• Evaluation	  of	  motor	  function	  with	  rotating	  rod	  test;	  
• Amylase	  and	  lipase	  assays;	  
• Total	  protease	  assays;	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4 RESULTS	  
4.1 PAPER	  I	  
Evaluation	  of	  motor	  coordination,	  measured	  as	   retention	   time	  on	  a	   rota-­‐rod,	  confirmed	  the	  
motor	  disability	  of	  LXRβ-­‐/-­‐	  mice	  already	  evident	   from	  5	  months	  of	  age.	  Administration	  of	  β-­‐
sitosterol	   did	  not	   affect	  motor	   function	   in	  WT	  mice	   at	   any	   age	  but	  markedly	  worsened	   the	  
disability	  of	  LXRβ-­‐/-­‐	  mice	  so	  that,	  at	  16	  months	  of	  age,	  they	  were	  almost	  paralyzed.	  
The	   histopathological	   study	   of	   the	   lateroventricular	   horn	   of	   the	   spinal	   cord	   (L1)	   showed	   a	  
drastic	   reduction	   in	   the	   number	   of	  motor	   neurons	   in	   LXRβ-­‐/-­‐	  mice	   after	   treatment	  with	   β-­‐
sitosterol.	   In	   the	   few	   motor	   neurons	   left	   in	   LXRβ-­‐/-­‐	   mice,	   it	   was	   possible	   to	   localize	  
cytoplasmatic	  inclusions	  positive	  for	  TDP-­‐43	  and	  ubiquitin,	  typical	  feature	  of	  ALS.	  
Analysis	   of	   the	   substantia	   nigra	   demonstrated	   that	   dopaminergic	   neurons	   of	   β-­‐sitosterol-­‐
treated-­‐LXRβ-­‐/-­‐	   mice	   were	   shrunken	   with	   reduced	   number	   of	   projections.	   Besides,	   the	  
number	  of	  activated	  microglia	  was	  higher	   in	  the	  pars	  reticulata	  of	  LXRβ-­‐/-­‐	  mice	  treated	  with	  
vehicle	   or	   β-­‐sitosterol.	   These	   data	   demonstrated	   that	   when	   LXRβ	   signaling	   is	   abnormal,	  
ingestion	  of	  β-­‐sitosterol	  can	  damage	  both	  the	  spinal	  cord	  and	  the	  substantia	  nigra	  as	  is	  seen	  in	  
ALS-­‐PDC.	  
To	  evaluate	  if	  a	  decreased	  intestinal	  clearance	  of	  β-­‐sitosterol	  could	  lead	  to	  an	  increase	  in	   its	  
uptake,	   mRNA	   levels	   of	   ABCG5/G8	   and	   serum	   levels	   of	   β-­‐sitosterol	   were	   determined.	  
Interestingly,	   these	   parameters	   were	   unaffected	   by	   either	   LXRβ	   deletion	   or	   β-­‐sitosterol	  
treatment,	  indicating	  a	  main	  role	  of	  LXRα	  in	  controlling	  these	  transporters.	  
Moreover,	  brain	  levels	  of	  cholesterol	  were	  decreased	  both	  in	  WT	  and	  in	  LXRβ-­‐/-­‐	  mice	  after	  β-­‐
sitosterol	   treatment	  suggesting	  a	   role	   for	  β-­‐sitosterol	   in	   inducing	  cholesterol	  clearance	   from	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4.2 PAPER	  II	  
Anthropometric	   measurements	   showed	   that	   both	   male	   and	   female	   LXRβ-­‐/-­‐	   mice	   had	  
significantly	   lower	  body	  weights,	  weight/length	   ratios	  and	  perigonadal	   fat	  pad	  size	   than	  WT	  
mice.	   Interestingly,	   the	   caloric	   intake	  monitored	   for	   1	  week	  was	   not	   different	   between	   the	  
four	  genotypes	  in	  male	  mice,	  whereas	  a	  significant	  increase	  in	  the	  caloric	  intake	  was	  detected	  
in	  LXRβ-­‐/-­‐	  female	  mice	  that	  despite	  the	  augmented	  caloric	  intake,	  did	  not	  gain	  weight.	  
Evaluation	  of	  pancreatic	  function	  demonstrated	  a	  reduced	  activity	  of	  α-­‐amylase	  and	  lipase	  in	  
serum	   of	   both	   LXRβ-­‐/-­‐	  male	   and	   female	  mice,	   compared	   to	  WT.	   Total	   protease	   in	   the	   gut,	  
considered	   an	   indirect	   index	   of	   pancreatic	   secretion,	   was	   measured	   using	   Azo-­‐casein	   as	   a	  
substrate.	  A	  drastic	  reduction	  of	  proteolytic	  activity	  in	  the	  feces	  was	  evident	  in	  the	  transgenic	  
animals	  of	  both	  sexes.	  
Histopathological	   analysis	   of	   LXRβ-­‐/-­‐	   pancreas	   showed	   a	   massive	   inflammatory	   infiltrate	  
around	   large	   and	   medium-­‐size	   pancreatic	   ducts	   that	   exhibited	   a	   high	   rate	   of	   cell	   death,	  
without	   any	   compensatory	   proliferation,	   in	   the	   ductal	   epithelium.	   Electron	   microscopic	  
studies	  of	   the	  transgenic	  pancreas	  revealed	  a	  dilatation	  of	   the	  ducts	  with	  dense	   intra-­‐ductal	  
material,	  including	  “scroll-­‐like”	  structures	  commonly	  seen	  in	  cystic	  fibrosis.	  
With	  specific	  antibodies,	  we	  studied	  the	  expression	  of	  LXRβ	  and	  the	  water	  channel,	  aquaporin-­‐
1	  in	  the	  ductal	  epithelium	  of	  the	  pancreas.	  In	  wild	  type	  mice,	  ductal	  epithelial	  cells	  expressed	  
LXRβ	  in	  the	  nuclei	  and	  aquaporin-­‐1	  on	  the	  plasma	  membrane.	  Interestingly,	  aquaporin-­‐1	  was	  
almost	  undetectable	  on	  the	  luminal	  surface	  of	  pancreatic	  duct	  epithelial	  cells	  and,	  in	  parallel,	  
mRNA	  levels	  of	  aquaporin-­‐1	  were	  reduced	  in	  LXRβ-­‐/-­‐	  mice,	  compared	  to	  WT.	  
To	  test	  the	  possibility	  that	  AQP-­‐1	  could	  be	  a	  target	  gene	  of	  LXRβ,	  WT	  mice	  were	  treated	  with	  
LXR-­‐agonist	  (T0901317)	  for	  7	  days;	  after	  treatment,	   levels	  of	  AQP-­‐1	  mRNA	  were	  significantly	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4.3 PAPER	  III	  
Expression	   of	   AQP-­‐1	   and	   AQP-­‐8	   in	   the	   gallbladder	   was	   studied	   with	   RT-­‐PCR	   and	   with	  
immunohistochemistry.	   In	  LXRβ-­‐/-­‐	  gallbladders,	  mRNA	  levels	  of	  both	  AQP-­‐1	  and	  AQP-­‐8	  were	  
significantly	  reduced	  compared	  to	  WT	  and	  their	  characteristic	  immunoreactivity	  on	  the	  plasma	  
membrane	  (apical-­‐baso-­‐lateral	  for	  AQP-­‐1	  and	  apical	  for	  AQP-­‐8)	  was	  not	  detectable	  as	   in	  WT	  
mice.	  The	  pattern	  of	  expression	  of	  water	  channels	   in	  LXRα-­‐/-­‐	  gallbladders	  was	  similar	  to	  WT	  
indicating	   a	   possible	   specific	   role	   of	   LXRβ	   in	   controlling	   AQP-­‐1	   and	   AQP-­‐8.	   Moreover,	  
treatment	   of	  WT	  mice	   with	   LXR	   agonist	   (T0901317)	   induced	   the	   gene	   expression	   of	   water	  
channels	  as	  well	  as	  the	  cholesterol	  transporters	  ABCG5/G8,	  known	  target	  genes	  of	  LXR,	  in	  the	  
gallbladder.	   Also	   the	   immunoreactivity	   of	   AQP-­‐1	   was	   much	   stronger	   in	   treated	   WT	  
gallbladders.	   Administration	   of	   LXR	   agonist	   to	   LXRβ-­‐/-­‐	  mice	   did	   not	   lead	   to	   any	   increase	   in	  
protein	  expression	  of	  AQP-­‐1,	  detected	  and	  quantified	  by	  iEM.	  
Morphologically,	  gallbladders	  of	  LXRβ-­‐/-­‐	  and	  WT	  mice	  had	  similar	  volume	  and	  gross	  anatomy	  
while	   WT-­‐LXR-­‐agonist	   treated	   mice	   showed	   a	   fasted	   reduced	   gallbladder	   volume	   with	   the	  
presence	  of	  abundant	  cholesterol	  crystals	  in	  the	  bile.	  
At	  microscopic	  level,	  LXRβ-­‐/-­‐	  cholangiocytes	  showed	  a	  loss	  of	  cell	  polarity	  and	  at	  TEM	  level	  a	  
conical	   shape	   with	   abundant	   electron-­‐dense	   material	   together	   with	   osmiophilic	   lamellar	  
bodies	  in	  dilated	  extracellular	  spaces.	  
	  
4.4 PAPER	  IV	  
At	  the	  age	  of	  11	  months,	  LXRβ-­‐/-­‐	  female	  mice	  were	  affected	  by	  a	  severe	  gallbladder	  disease:	  a	  
wide	   range	   of	   preneoplastic	   lesions	   like	   dysplasia,	   metaplasia,	   hyperplasia	   and	   adenomas	  
were	  detectable.	  These	  lesions	  degenerated	  to	  cancer	  that	  was	  evident	  in	  19	  months	  old	  mice.	  
Assessment	  of	  proliferation,	  performed	  with	  PCNA	  staining,	  showed	  an	  increased	  proliferation	  
rate	  in	  LXRβ-­‐/-­‐	  mice	  starting	  from	  4	  months,	  when,	  interestingly,	  the	  gallbladder	  morphology	  
was	   normal.	   A	   compensatory	   increased	   cell	   death	   rate,	   studied	   with	   TUNEL	   staining,	   was	  
detectable	  at	  this	  age,	  but	  it	  decreased	  markedly	  when	  the	  preneoplastic	  lesions	  developed.	  
  25 
Surprisingly,	  the	  gallbladders	  of	  female	  and	  male	  LXRα-­‐/-­‐	  and	  LXRα-­‐/-­‐β-­‐/-­‐	  mice	  as	  well	  as	  male	  
LXRβ-­‐/-­‐	  mice	  were	  unaffected.	  
Mechanistically,	  TGFβ	  signaling	  seems	  to	  be	  involved	  in	  the	  neoplastic	  gallbladder	  phenotype	  
since	   increased	  expression	  of	  down-­‐stream	  genes	  of	  TGFβ	   (pSMAD2-­‐3),	   leading	  to	   loss	  of	  E-­‐
cadherin,	  was	  evident	  in	  LXRβ-­‐/-­‐	  female	  gallbladders.	  
The	  prevalence	  of	  gallbladder	  disease	  only	  in	  female	  mice	  together	  with	  the	  high	  incidence	  of	  
the	  disease	  in	  women	  [115]	  motivated	  a	  study	  regarding	  a	  possible	  role	  of	  sexual	  hormones	  in	  
the	   interplay	   between	   LXRβ	   and	   TGFβ.	   LXRβ-­‐/-­‐	   mice	   were	   ovariectomized	   at	   3	   months.	  
Surprisingly,	   at	   12	   months	   of	   age,	   no	   morphological	   alterations	   were	   detectable	   in	   the	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5 DISCUSSION	  
Results	   of	  paper	   I	   demonstrated	   that	   in	   LXRβ-­‐/-­‐	  mice,	   ingestion	   of	   β-­‐sitosterol	   has	  marked	  
neurodegenerative	   consequences	   both	   in	   the	   spinal	   cord	   and	   in	   the	   substantia	   nigra,	  
resembling	  a	  phenotype	  similar	  to	  ALS-­‐PDC.	  
Although	  LXRs	  are	   involved	   in	  overall	  cholesterol	  homeostasis,	  blood	  cholesterol	   levels	  were	  
not	  affected	  either	  by	  LXRβ	  deletion	  or	  β-­‐sitosterol	   treatment.	  However,	   LXRβ-­‐/-­‐	  mice	  were	  
characterized	   by	   lipid	   inclusions	   in	   motor	   neurons	   of	   the	   spinal	   cord	   and	   high	   cholesterol	  
levels	   in	   the	   brain.	   After	   β-­‐sitosterol	   treatment,	   there	   was	   a	   decrease	   in	   brain	   cholesterol	  
levels	  while	  in	  the	  spinal	  cord	  it	  was	  difficult	  to	  evaluate	  changes	  in	  lipid	  inclusions,	  because	  of	  
low	  number	  of	  motor	  neurons	  left.	  
We	   interpret	   this	   data	   to	   mean	   that	   β-­‐sitosterol,	   an	   activator	   of	   both	   LXRα	   and	   LXRβ,	  
stimulates	   LXRα	   in	   LXRβ-­‐/-­‐	   mice	   promoting	   cholesterol	   excretion	   from	   the	   brain.	   	   Further	  
evidence	  of	  an	  increase	  in	  cholesterol	  elimination	  from	  the	  brain	  is	  the	  high	  level	  of	  brain	  24-­‐
hydroxycholesterol	  in	  β-­‐sitosterol-­‐treated	  LXRβ-­‐/-­‐	  mice.	  
Maintenance	   of	   appropriate	   cholesterol	   balance	   in	   the	   brain	   is	   crucial	   for	   many	   signal	  
pathways	   like	   synaptic	   vesicle	   turnover,	   function	   of	   calcium	   channels,	   neurotransmitter	  
release,	  signaling	  of	  GABA	  and	  glutamate.	  Our	  studies	  show	  that	  when	  cholesterol	  levels	  are	  
affected	  in	  either	  direction,	  mice	  demonstrate	  a	  neurological	  phenotype	  (table	  3).	  
	   	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Table	  3:	  summary	  of	  the	  main	  cholesterol	  imbalances	  in	  LXRβ-­‐/-­‐	  male	  mice.	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Paper	  II	  demonstrates	  that	  pancreatic	  exocrine	  function	  is	  severely	  affected	  in	  LXRβ-­‐/-­‐	  
mice,	  as	  shown	  by	  low	  levels	  of	  serum	  amylase	  and	  lipase,	  low	  levels	  of	  fecal	  total	  protease,	  
massive	   infiltration	  of	   immune	  cells	  all	  around	  pancreatic	  ducts	  with	   increased	  cell	  death	  of	  
the	  ductal	   epithelium	  and	  dense	   secretion	  obstructing	   the	   lumen	  of	   intralobular	   ducts.	   The	  
cause	   of	   dense	   pancreatic	   secretions	   seems	   to	   be	   the	   reduced	   expression	  of	  AQP-­‐1	   on	   the	  
luminal	  surface	  of	  pancreatic	  ductal	  epithelial	  cells.	  AQP-­‐1	   is	  a	  water	  channel	  protein	  with	  a	  
key	  role	  in	  trans-­‐cellular	  fluid	  transport.	  AQP-­‐1-­‐/-­‐	  mice	  demonstrate	  mild	  growth	  retardation	  
on	  standard	  diet	   [135]	  and,	  when	  fed	  with	  a	  high-­‐fat	  diet,	   they	  are	  resistant	  to	  weight-­‐gain,	  
develop	   steatorrhea	   and	   have	   a	   decreased	   concentration	   of	   amylase	   and	   lipase	   in	   the	  
pancreatic	  fluid	  [136].	  It	  seems	  that	  defective	  secretion	  of	  water	  in	  the	  pancreatic	  ducts	  leads	  
to	  a	  modification	  in	  the	  composition	  of	  pancreatic	  juice	  that	  damages	  the	  pancreatic	  epithelia	  
and	  finally	  leads	  to	  exocrine	  insufficiency.	  
In	   the	   digestive	   system	   AQP-­‐1	   is	   expressed	   in	   endothelial	   cells	   of	   capillaries,	   small	  
vessels	   and	   lymphatic	   capillaries	   of	   the	   small	   intestine	   [137],	   in	   cholangiocytes	   of	   liver,	   bile	  
ducts	   [138]	   and	   gallbladder	   [139]	   and	   in	   the	   inter-­‐	   and	   intralobular	   pancreatic	   ducts	   [140]	  
where	  it	  seems	  to	  participate	  in	  bile	  and	  pancreatic	  juice	  formation.	  
In	  paper	   III	   the	  expression	  of	  AQPs	   is	   further	   investigated	   in	   the	  gallbladder,	  one	  of	  
the	   most	   active	   water-­‐transporting	   organs	   of	   the	   digestive	   system.	   LXRβ-­‐/-­‐	   cholangiocytes	  
show	  a	  markedly	   reduced	  expression	  of	  AQP-­‐1	  and	  AQP-­‐8	  both	  at	  mRNA	  and	  protein	   levels	  
while	  LXR-­‐activation	  with	  synthetic	  ligand	  increases	  their	  expression	  in	  WT	  animals	  but	  not	  in	  
LXRβ-­‐/-­‐	   mice.	   Morphologically,	   in	   male	   LXRβ-­‐/-­‐	   mice,	   the	   reduced	   AQP-­‐1	   expression	   in	  
gallbladder	  cholangiocytes	  is	  associated	  with	  thinner	  gallbladder	  wall,	  loss	  of	  cell	  polarity	  and	  
accumulation	  of	  osmiophilic	  lamellar	  bodies	  in	  the	  extracellular	  spaces.	  
The	   lack	   of	   increase	   in	   AQP-­‐1	   content	   in	   LXRβ-­‐/-­‐	   mice	   treated	   with	   LXR	   agonist,	  
together	  with	  the	  normal	  profile	  of	  the	  same	  AQPs	  in	  LXRα-­‐/-­‐	  mice	  indicates	  that	  specifically	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the	  β	  isoform	  of	  LXR	  may	  be	  the	  transcriptional	  controller	  of	  water	  channels	  in	  the	  gallbladder	  
and	  pancreas.	  
In	   support	   of	   this	   notion	   is	   the	   fact	   that	   LXRβ-­‐/-­‐	   mice	   share	   important	   phenotypical	  
characteristics	   with	   AQP-­‐1-­‐/-­‐	   mice:	   resistance	   to	   gain	   weight	   [136,	   141],	   a	   severe	   polyuria	  
(Gabbi	  C.	  unpublished	  results)	  and	  alterations	  in	  the	  skin	  [142],	  testicles	  [143-­‐145],	  lungs	  and	  
salivary	   glands	   (Gabbi	   C.	   unpublished	   results)	   that	   could	   be	   explained	   at	   least	   in	   part	   by	   a	  
defective	   water	   transport.	   Indeed,	   AQP-­‐1,	   expressed	   in	   the	   kidney	   proximal	   tubule,	  
descending	   limb	  of	  Henle,	  and	   in	  vasa	   recta,	   is	  a	  key	  player	   in	  water	   reabsorption	   from	  the	  
urine	  explaining	  the	  severe	  polyuria	  and	  inability	  to	  concentrate	  urine	  in	  AQP-­‐1-­‐/-­‐	  mice	  [146,	  
147]	  and	  in	  LXRβ-­‐/-­‐	  mice	  (Gabbi	  C,	  unpublished	  results).	  
In	  the	  CNS,	  strong	  expression	  of	  AQP-­‐1	  has	  been	  described	  on	  the	  luminal	  surface	  of	  
the	   choroid	  plexus	  epithelium	   [148,	  149],	   the	  main	   site	  of	  production	  of	   cerebrospinal	   fluid	  
(CSF).	  This	  fluid	  not	  only	  provides	  physical	  support	  in	  the	  CNS	  but	  also	  facilitates	  transport	  of	  
nutrients	  in	  the	  subarachnoid	  space	  surrounding	  the	  brain	  and	  the	  spinal	  cord	  [150].	  In	  mice	  
lacking	  AQP-­‐1	   there	   is	   a	  25%	   reduction	   in	  CSF	  production,	   compared	   to	  WT	   [151].	  We	  may	  
speculate	  that	  there	  could	  be	  a	  reduction	  in	  AQP-­‐1	  expression	  in	  the	  choroid	  plexus	  of	  LXRβ-­‐/-­‐	  
mice.	   Such	   a	   reduction	   would	   lead	   to	   electrolyte	   imbalances	   and	   nutrient	   deficiencies	   and	  
could	  be	  the	  one	  of	  the	  causes	  of	  the	  pathogenesis	  of	  neurodegenerative	  diseases	  in	  LXRβ-­‐/-­‐	  
mice.	  
Female	  LXRβ-­‐/-­‐	  gallbladders,	  studied	   in	  paper	   IV,	  are	  characterized	  by	   increased	  cell	  
proliferation	   at	   the	   age	   of	   4	   months,	   by	   the	   presence	   of	   numerous	   pre-­‐neoplastic	   lesions	  
(adenomas,	  dysplasia,	  metaplasia)	  at	  the	  age	  of	  11	  months,	  degenerating	  to	  carcinomas	  at	  19	  
months.	  
Carcinogenesis	  of	  the	  gallbladder,	  estimated	  to	  occur	  within	  a	  time	  frame	  of	  15	  years	  
in	  humans	  [152],	   is	  a	   long	  process	   in	  which	  a	  concert	  of	  numerous	  “hits”	  participates	   in	  the	  
neoplastic	   transformation	   of	   the	   epithelium	   [115].	   In	   LXRβ-­‐/-­‐	   female	   mice	   several	   hitting	  
factors	  have	  been	   identified.	   First	   seems	   to	  be	  an	   increased	   inflammatory	   reaction,	  evident	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histologically	   from	   the	   constant	   background	   of	   cholecystitis	   in	   the	   preneoplastic	   lesions	   of	  
LXRβ-­‐/-­‐	  gallbladders.	  LXRβ	  has	  been	  described	  to	  have	  a	  potent	  anti-­‐inflammatory	  activity	  [55]	  
by	   transrepressing	   the	   NF-­‐kB	   signal,	   therefore,	   its	   absence	   induces	   a	   cascade	   of	   NF-­‐kB	  
mediated	   events	   that	   may	   trigger	   inflammation	   and	   drive	   it	   into	   cancer	   [153,	   154].	  
Interestingly,	   in	   humans,	   infection	   with	   numerous	   microbial	   agents	   (S.typhi,	   H.	   bilis,	   H.	  
hepaticus,	   E.coli)	   has	   been	   described	   in	   association	   with	   gallbladder	   cancer	   [155].	   Besides,	  
LXRα-­‐/-­‐β-­‐/-­‐	  mice	  have	  been	  shown	  to	  be	  more	  susceptible	  to	  infections	  [156].	  Speculatively,	  
bacteria	  may	   not	   only	   induce	   inflammation	   directly	   but	   also,	   by	   activating	   TLR3/4	   [70],	   be	  
responsible	   for	   an	   inhibition	   of	   LXR	   activity	   and	   therefore	   reinforcing	   an	   inflammatory	  
reaction.	  
Another	   factor	   in	   gallbladder	   carcinogenesis	   in	   LXRβ-­‐/-­‐	  mice	   is	   a	   complex	   interplay	  
between	  TGFβ	  and	  estrogens.	  Downstream	  genes	  of	  TGFβ	  appear	  to	  be	  upregulated	  in	  LXRβ-­‐
/-­‐	  female	  transformed	  gallbladders	  and,	  surprisingly,	  ovariectomy	  prevents	  the	  development	  
of	  pre-­‐neoplastic	   lesions	  and	  reduces	  TGFβ	   signaling.	  Despite	  strong	  epidemiological	  data	   in	  
humans	   (high	   gallbladder	   cancer	   incidence	   in	   females	   and	   a	   positive	   association	  with	   HRT)	  
[115]	   indicating	   a	   crucial	   pathogenetic	   role	   for	   estrogens,	   as	   well	   as	   a	   correlation	   of	   TGFβ	  
polymorphism	  with	  gallbladder	  cancer	  [157],	  many	  aspects	  of	  this	  interplay	  remain	  unclear.	  To	  
be	  considered	  also	  that	  although	  in	  LXRβ-­‐/-­‐	  female	  mice,	  no	  differences	  in	  the	  expression	  of	  
ERα	   and	  ERβ	   proteins	  have	  been	  detected	   compared	   to	  WT,	   an	   imbalance	   in	   their	   activity,	  
influencing	  LXRβ/TGFβ	  interplay	  may	  not	  be	  excluded.	  
Moreover,	  a	  direct	  action	  of	  LXRβ	  on	  cell	  cycle	  control,	  as	  shown	  in	  several	  cell	  culture	  
systems	  [158]	  has	  to	  be	  considered	  in	  the	  transformation	  of	  LXRβ-­‐/-­‐	  gallbladder	  epithelium.	  
	  The	  contribution	  of	  AQP-­‐1	  in	  carcinogenesis	  should	  also	  be	  considered.	  Indeed	  AQPs,	  
are	   not	   only	  mediators	   of	   water	   transport	   but	   they	   are	   also	   involved	   in	   cell	   adhesion	   and	  
migration	  [159]	  with	  an	  emerging	  role	  in	  tumorigenesis	  and	  metastasis	  formation	  [160,	  161].	  
AQP-­‐1	  expression	  is	  affected	  in	  numerous	  human	  cancers;	  in	  particular	  in	  cholangiocarcinoma,	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AQP-­‐1	  appears	   to	  be	  downregulated	  and	   its	   low	  expression	   correlates	  with	  poor	  prognosis,	  










	   	   	  
	   Figure	  3.	  Hypothesis	  for	  the	  cascade	  of	  events	  following	  LXRβ	  deficiency.	  
Knocking-­‐out	   LXRβ	   in	   mice	   leads	   to	   (i)	   cholesterol	   accumulation	   in	   the	   big	   motor	  
neuron	   of	   the	   spinal	   cord	   that	   contributes	   to	   neurodegeneration	   in	   male	   mice;	   (ii)	  
reduced	   aquaporin-­‐1	   expression	   that	   is	   responsible	   for	   a	   pancreatic	   exocrine	  
insufficiency,	   malignant	   transformation	   of	   gallbladder	   cholangiocytes,	   reduced	   CSF	  
production;	   (iii)	   increased	  (iv)	   inflammation,	   (v)	  proliferation	  and	  (vi)	  TGFβ	   signalling	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Several	  studies	  have	  examined	  the	  roles	  of	  nutrients	  as	  environmental	  factors	  that,	  in	  
concert	   with	   genetic	   predisposition,	   could	   contribute	   to	   the	   pathogenesis	   of	   ALS	   and	  
gallbladder	   cancer.	   Interestingly,	   a	   premorbid	   daily	   intake	   of	   n-­‐3	   polyunsatured	   fatty	   acids	  
(PUFA)	  and	  vitamin	  E	  has	  been	  shown	  to	  be	  significantly	  lower	  in	  patients	  with	  ALS	  [163,	  164]	  
and	   Parkinson´s	   disease	   [165].	   In	   addition,	   low	   levels	   of	   vitamin	   E	   and	   other	   antioxidative	  
vitamins	  have	  been	  detected	  in	  patients	  affected	  by	  gallbladder	  cancer	  [166,	  167].	  Indeed	  n-­‐3	  
PUFA,	  acting	  as	  substrate	  in	  the	  synthesis	  of	  prostaglandins	  with	  anti-­‐inflammatory	  effects	  has	  
anti-­‐inflammatory	  [168],	  antineoplastic	  [169]	  and	  neuroprotective	  actions	  [170].	  Vitamin	  E	   is	  
an	  antioxidant	  agent	  that	  prevents	  lipid	  peroxidation	  and	  acts	  as	  a	  neuroprotective	  factor	  both	  
in	  humans	  [171]	  and	  in	  animal	  models	  of	  ALS	  [172].	  
During	   pancreatic	   exocrine	   insufficiency,	   the	   lack	   of	   pancreatic	   lipolytic	   enzymes	   in	   the	  
intestinal	   lumen	   affects	   the	   absorption	   of	   lipids,	   in	   particular	   triglycerides,	   from	   the	   diet	  
leading	  to	  a	  reduced	  uptake	  of	  PUFA	  and	  vitamins	  (as	  vitamin	  E)	  that	  require	  lipid	  micells	  to	  be	  
absorbed.	   Interestingly,	   although	   no	   primary	   pancreatic	   involvement	   in	   ALS	   has	   been	  
described,	   it	   has	   been	   shown	   that	   patients	   affected	   by	   ALS,	   have	   a	   reduced	   exocrine	  
pancreatic	  function	  in	  particular	  after	  secretion	  stimulation	  [173].	  
We	  speculate	  (Figure	  3)	  that	  in	  LXRβ-­‐/-­‐	  male	  mice,	  the	  pancreatic	  exocrine	  insufficiency,	  which	  
appears	   at	   an	   early	   age,	   could	   be	   responsible	   of	   a	   lack	   in	   n-­‐3	   PUFA	   and	   vitamin	   E.	   These	  
deficiencies	   could	   lead	   to	   vulnerability	   to	   oxidative	   stress	   and	   inflammation	   and	   in	   turn	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6 CONCLUSIONS	  AND	  PERSPECTIVES	  
The	   articles	   in	   this	   thesis	   open	   up	   completely	   new	   perspectives	   in	   the	   specific	  
pathophysiological	  activity	  of	   the	  oxysterol	   receptor	  LXRβ	   in	  controlling	  not	  only	  cholesterol	  
homeostasis	   in	   central	  nervous	   system	  but	  also	  water	   channels	   in	  pancreas	  and	  gallbladder	  
and	  carcinogenesis	  in	  female	  gallbladders.	  
The	  observation	  that	  LXRβ	  is	  essential	  in	  maintaining	  the	  physiological	  response	  to	  β-­‐
sitosterol	   administration,	   suggests	   that	   LXRβ	   dysfunction	   could	   be	   a	   genetic	   predisposition	  
that,	   in	   the	   Guam	   population,	   in	   concert	   with	   environmental	   factors	   like	   phytosterols,	  
participates	  in	  the	  pathogenesis	  of	  ALS-­‐PDC.	  
The	   specific	   transcriptional	   control	   of	   water	   channels	   by	   LXRβ	   in	   pancreatic	   ductal	  
epithelial	  cells	  and	  gallbladder	  cholangiocytes,	  leads	  to	  a	  new	  perspective	  on	  LXRβ	  function	  in	  
diseases	   associated	   with	   a	   dysregulation	   of	   the	   gastrointestinal	   fluid	   balance	   such	   as	   in	  
pancreatic	  insufficiency	  or	  cystic	  fibrosis.	  
More	  studies	  are	  required	  to	  investigate	  the	  mechanism	  of	  transcriptional	  control	  of	  
LXRβ	   over	  AQPs	   focusing	   in	   particular	   on	   the	   identification	   of	   possible	   LXR-­‐binding	   sites	   on	  
AQP	  genes.	  A	  crucial	  factor	  that	  remains	  to	  be	  investigated	  is	  the	  role	  of	  sexual	  hormones	  in	  
influencing	  LXRβ	  activity,	  given	  that	  only	  LXRβ-­‐/-­‐	  male	  mice	  are	  affected	  by	  ALS	  and	  only	  LXRβ-­‐
/-­‐	  female	  mice	  present	  the	  gallbladder	  carcinogenesis	  that	  is	  prevented	  by	  ovariectomy.	  
Further	  studies	  are	  planned	  in	  order	  to	  identify	  the	  role	  of	  LXRβ	  in	  human	  diseases	  in	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